IndustryCompany release

BMS raises 2026 revenue guidance after third-quarter sales climb 7% to $13.1bn

🇺🇸 Bristol Myers Squibb Co (BMY) · Thu 29 Oct 2026

Bristol Myers Squibb lifted its full-year revenue outlook as Growth Portfolio sales rose 12%, citing the approval of Zenbexus and positive late-stage iza-bren data.

Bristol Myers Squibb reported third-quarter 2026 results on 29 October, with revenue up 7% to $13.1bn. Sales from its Growth Portfolio rose 12%, outpacing the company total.

Profit measures were weighed down by charges for acquired in-process research and development (IPRD). GAAP earnings per share were $1.05, while non-GAAP earnings per share were $1.35.

The company raised its full-year 2026 revenue guidance to a range of $49.75bn to $50.25bn. It did not specify the previous range in the material available.

BMS pointed to two pipeline developments behind its outlook: the approval of Zenbexus, described as a first-in-class CELMoD for multiple myeloma, and positive late-stage data for iza-bren. The summary provided does not give the approving authority, the indication details or the trial results.

What it means for your team

  • Regulatory teams tracking multiple myeloma should note that Zenbexus is described as a first-in-class CELMoD, so the approving authority's label and conditions will be worth reviewing once available.
  • Positive late-stage iza-bren data may point to future filings, though timelines and regions have not been disclosed.
  • Market-access teams may want to watch how Growth Portfolio products feature in payer and pricing discussions, given the 12% sales increase.
  • Acquired IPRD charges show that business development is affecting reported earnings, which is relevant for those monitoring portfolio changes.

Company's press release (SEC filing): Bristol Myers Squibb Co ↗

Article written by VigiEye from the official source (Bristol Myers Squibb Co). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →